Enanta Pharmaceuticals (ENTA) Free Cash Flow: 2012-2025
Historic Free Cash Flow for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$7.9 million.
- Enanta Pharmaceuticals' Free Cash Flow rose 58.93% to -$7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.2 million, marking a year-over-year increase of 66.74%. This contributed to the annual value of -$32.2 million for FY2025, which is 66.74% up from last year.
- Latest data reveals that Enanta Pharmaceuticals reported Free Cash Flow of -$7.9 million as of Q3 2025, which was down 145.80% from $17.4 million recorded in Q2 2025.
- Over the past 5 years, Enanta Pharmaceuticals' Free Cash Flow peaked at $17.4 million during Q2 2025, and registered a low of -$38.8 million during Q4 2022.
- Its 3-year average for Free Cash Flow is -$18.4 million, with a median of -$21.0 million in 2024.
- As far as peak fluctuations go, Enanta Pharmaceuticals' Free Cash Flow crashed by 528.12% in 2021, and later spiked by 182.70% in 2025.
- Over the past 5 years, Enanta Pharmaceuticals' Free Cash Flow (Quarterly) stood at -$13.6 million in 2021, then tumbled by 184.56% to -$38.8 million in 2022, then skyrocketed by 33.56% to -$25.8 million in 2023, then increased by 0.89% to -$25.5 million in 2024, then surged by 58.93% to -$7.9 million in 2025.
- Its Free Cash Flow stands at -$7.9 million for Q3 2025, versus $17.4 million for Q2 2025 and -$16.0 million for Q1 2025.